Galera Therapeutics

General Information


We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Our lead product candidate, GC4419, is a potent and highly selective small molecule dismutase mimetic we are initially developing for the reduction of severe oral mucositis, or SOM. SOM is a common, debilitating complication of radiotherapy in patients with head and neck cancer, or HNC.

Employees: 26
Founded: 2012
Contact Information
Address 2 W Liberty Blvd #100, Malvern, PA 19355, US
Phone Number (610) 725-1500
Web Address
View Prospectus: Galera Therapeutics
Financial Information
Market Cap $3654mil
Revenues $0 mil (last 12 months)
Net Income $-43.3 mil (last 12 months)
IPO Profile
Symbol GRTX
Exchange NASDAQ
Shares (millions): 5.0
Price range $12.00 - $12.00
Est. $ Volume $60.0 mil
Manager / Joint Managers BofA Securities/ Citigroup/ Credit Suisse
CO-Managers BTIG
Expected To Trade: 11/7/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change